Literature DB >> 23929317

Risk factors for human herpesvirus 6 reactivation and its relationship with syndrome of inappropriate antidiuretic hormone secretion after stem cell transplantation in pediatric patients.

Naohisa Toriumi1, Ryoji Kobayashi, Makoto Yoshida, Akihiro Iguchi, Takeo Sarashina, Hitoshi Okubo, Daisuke Suzuki, Hirozumi Sano, Masao Ogata, Hiroshi Azuma.   

Abstract

There have been several reports on the reactivation of human herpesvirus 6 (HHV6) after stem cell transplantation (SCT) in adults, which sometimes induces severe illness. Few reports exist on pediatric patients; therefore, we retrospectively examined HHV6 reactivation after SCT in children. We reviewed 80 patients with a median age of 6 years. We analyzed HHV6 DNA serum samples from the patients before SCT and at 20 and 40 days after SCT using polymerase chain reaction. We also analyzed the relationship between HHV6 reactivation and the syndrome of inappropriate antidiuretic hormone secretion (SIADH). At 20 days after SCT, 35.0% of serum samples were positive for HHV6 DNA. The median viral load was 3.1×10 copies/mL serum. Multivariate analysis showed cord blood transplantation as the only risk factor for HHV6 reactivation. HHV6 reactivation occurs in 59.4% of 32 patients who underwent cord blood transplantation and in 18.8% of 48 patients who underwent SCT from other sources. Among the 14 patients with SIADH, 78.6% experienced HHV6 reactivation. Among the 66 patients without SIADH, only 25.8% had HHV6 reactivation. This result was statistically significant (P<0.001). This analysis revealed that HHV6 reactivation occurs in many children. In addition, HHV6 reactivation plus SIADH should prompt evaluation for central nervous system disease.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 23929317     DOI: 10.1097/MPH.0b013e3182a11676

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  4 in total

1.  Hyponatremia associated with human herpesvirus-6 (HHV-6) encephalitis after allogeneic hematopoietic stem cell transplantation: A presentation different from HHV-6 myelitis.

Authors:  Koichi Murakami; Sumiko Kohashi; Masatoshi Sakurai; Jun Kato; Takaaki Toyama; Yuya Koda; Yusuke Yamane; Risa Hashida; Ryohei Abe; Rie Yamazaki; Taku Kikuchi; Takayuki Shimizu; Shigeaki Suzuki; Naoki Hasegawa; Shinichiro Okamoto; Takehiko Mori
Journal:  Int J Hematol       Date:  2017-05-13       Impact factor: 2.490

Review 2.  Clinical practice recommendations for the diagnosis and management of human herpesvirus-6B encephalitis after allogeneic hematopoietic stem cell transplantation: the Japan Society for Hematopoietic Cell Transplantation.

Authors:  Masao Ogata; Naoyuki Uchida; Takahiro Fukuda; Kazuhiro Ikegame; Tomohiko Kamimura; Makoto Onizuka; Koji Kato; Hikaru Kobayashi; Yoji Sasahara; Masashi Sawa; Akihisa Sawada; Daiichiro Hasegawa; Masayoshi Masuko; Toshihiro Miyamoto; Shinichiro Okamoto
Journal:  Bone Marrow Transplant       Date:  2019-11-19       Impact factor: 5.483

Review 3.  Human herpesvirus-6 encephalitis after allogeneic hematopoietic cell transplantation: what we do and do not know.

Authors:  M Ogata; T Fukuda; T Teshima
Journal:  Bone Marrow Transplant       Date:  2015-04-27       Impact factor: 5.483

4.  Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT.

Authors:  Anastasia Papadopoulou; Ulrike Gerdemann; Usha L Katari; Ifigenia Tzannou; Hao Liu; Caridad Martinez; Kathryn Leung; George Carrum; Adrian P Gee; Juan F Vera; Robert A Krance; Malcolm K Brenner; Cliona M Rooney; Helen E Heslop; Ann M Leen
Journal:  Sci Transl Med       Date:  2014-06-25       Impact factor: 17.956

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.